PMID- 31028202
OWN - NLM
STAT- MEDLINE
DCOM- 20190820
LR  - 20230328
IS  - 1791-7549 (Electronic)
IS  - 0258-851X (Print)
IS  - 0258-851X (Linking)
VI  - 33
IP  - 3
DP  - 2019 May-Jun
TI  - Combined EGFR/ALK Expression Analysis in Laryngeal Squamous Cell Carcinoma.
PG  - 815-819
LID - 10.21873/invivo.11544 [doi]
AB  - BACKGROUND/AIM: Epidermal growth factor receptor (EGFR) acts as an oncogene in 
      malignancies. Our aim was to examine the role of combined EGFR/ anaplastic 
      lymphoma kinase (ALK) expression as molecular markers in laryngeal squamous cell 
      carcinoma (LSCC) patients. MATERIALS AND METHODS: Fifty (n=50) tissue sections 
      derived from twenty-five (n=25) primary LSCCs were analyzed by 
      immunohistochemistry (IHC). RESULTS: EGFR overexpression was observed in 17/25 
      (68%) cases. Concerning ALK, 23/25 (92%) demonstrated low expression. EGFR 
      expression was associated with grade (p=0.049), whereas ALK expression was 
      correlated with stage (p=0.048). ALK overexpression was detected at 
      advanced-stage EGFR-positive cases. A biphasic EGFR protein expression pattern 
      was observed in five (n=5) LSCC cases, whereas ALK expression was stable in all 
      cases. CONCLUSION: EGFR overexpression is frequently observed in LSCC combined 
      with low ALK expression. LSCC patients with EGFR/ALK protein overexpression 
      should be eligible for targeted therapeutic strategies.
CI  - Copyright(c) 2019, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Politi, Anastasia
AU  - Politi A
AD  - Department of Oncology, Medical School, University of Ioannina, Ioannina, Greece.
FAU - Tsiambas, Evangelos
AU  - Tsiambas E
AD  - Department of IHC & Molecular Biology, 401 GAH, Athens, Greece 
      tsiambasecyto@yahoo.gr.
FAU - Mastronikolis, Nicholas S
AU  - Mastronikolis NS
AD  - ENT Department, Medical School, University of Patras, Patras, Greece.
FAU - Peschos, Dimitrios
AU  - Peschos D
AD  - Department of Physiology, Medical School, University of Ioannina, Ioannina, 
      Greece.
FAU - Asproudis, Ioannis
AU  - Asproudis I
AD  - Department of Ophthalmology, Medical School, University of Ioannina, Ioannina, 
      Greece.
FAU - Kyrodimos, Efthymios
AU  - Kyrodimos E
AD  - 1ST ENT Department, Hippokration Hospital, National and Kapodistrian University 
      of Athens, Athens, Greece.
FAU - Armata, Ilianna E
AU  - Armata IE
AD  - Medical School, Cambridge University Hospital, Cambridge, U.K.
FAU - Chrysovergis, Aristeidis
AU  - Chrysovergis A
AD  - 1ST ENT Department, Hippokration Hospital, National and Kapodistrian University 
      of Athens, Athens, Greece.
FAU - Asimakopoulos, Asimakis
AU  - Asimakopoulos A
AD  - ENT Department, Luxembourg Hospital Center, Luxembourg, Luxembourg.
FAU - Papanikolaou, Vasileios S
AU  - Papanikolaou VS
AD  - 1ST ENT Department, Hippokration Hospital, National and Kapodistrian University 
      of Athens, Athens, Greece.
FAU - Batistatou, Anna
AU  - Batistatou A
AD  - Department of Pathology, Medical School, University of Ioannina, Ioannina, 
      Greece.
FAU - Ragos, Vasileios
AU  - Ragos V
AD  - Department of Maxillofacial, Medical School, University of Ioannina, Ioannina, 
      Greece.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - In Vivo
JT  - In vivo (Athens, Greece)
JID - 8806809
RN  - EC 2.7.10.1 (Anaplastic Lymphoma Kinase)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
MH  - Anaplastic Lymphoma Kinase/genetics/*metabolism
MH  - Carcinoma, Squamous Cell/genetics/*metabolism/pathology
MH  - ErbB Receptors/genetics/metabolism
MH  - Female
MH  - Gene Expression
MH  - Humans
MH  - Immunohistochemistry
MH  - Laryngeal Neoplasms/genetics/*metabolism/pathology
MH  - Male
MH  - Neoplasm Grading
MH  - Neoplasm Staging
PMC - PMC6559894
OTO - NOTNLM
OT  - ALK
OT  - Carcinoma
OT  - EGFR
OT  - larynx
COIS- The Authors declare no conflicts of interest regarding this study.
EDAT- 2019/04/28 06:00
MHDA- 2019/08/21 06:00
PMCR- 2019/05/03
CRDT- 2019/04/28 06:00
PHST- 2019/03/13 00:00 [received]
PHST- 2019/04/09 00:00 [revised]
PHST- 2019/04/10 00:00 [accepted]
PHST- 2019/04/28 06:00 [entrez]
PHST- 2019/04/28 06:00 [pubmed]
PHST- 2019/08/21 06:00 [medline]
PHST- 2019/05/03 00:00 [pmc-release]
AID - 33/3/815 [pii]
AID - 10.21873/invivo.11544 [doi]
PST - ppublish
SO  - In Vivo. 2019 May-Jun;33(3):815-819. doi: 10.21873/invivo.11544.